

ORAMED PHARMACEUTICALS INC.  
Form 8-K  
March 18, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2008

---

**ORAMED PHARMACEUTICALS INC.**  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

**000-50298**  
(Commission File Number)

**98-0376008**  
(IRS Employer  
Identification No.)

**2 Elza Street**  
**Jerusalem, Israel 93706**  
(Address of principal executive offices and zip code)

**Registrant's telephone number, including area code: 972-54-790-9058**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM REGULATION FD DISCLOSURE.**  
**7.01**

On March 18, 2008, the registrant issued a press release announcing that it has been granted approval to conduct a Phase 2A study of its oral insulin on diabetic volunteers. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

**ITEM FINANCIAL STATEMENTS AND EXHIBITS.**  
**9.01**

(c) Exhibits

99.1 Press Release, dated March 18, 2008.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ORAMED PHARMACEUTICALS INC.**

Dated: March 18, 2008

By: */s/ Nadav Kidron*  
Nadav Kidron  
President, CEO and Director